Search

Your search keyword '"Berk, John L"' showing total 124 results

Search Constraints

Start Over You searched for: Author "Berk, John L" Remove constraint Author: "Berk, John L" Database Unpaywall Remove constraint Database: Unpaywall
124 results on '"Berk, John L"'

Search Results

1. Impact de la sévérité de la polyneuropathie à baseline sur la réponse au traitement par le vutrisiran dans l’étude de phase 3 HELIOS-A

2. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy

3. Primary Results From APOLLO-B Open-label Extension Study Of Patisiran In Patients With Transthyretin Cardiac Amyloidosis

4. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis

5. Abstract 13273: APOLLO-B, a Study of Patisiran in Patients With Transthyretin Cardiac Amyloidosis: Primary Long-Term Results From the Open-Label Extension Period

6. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

8. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen

9. 77 HELIOS-A: 18-MONTH EXPLORATORY CARDIAC RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS

10. 137 PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY

12. Liver‐directed drugs for transthyretin‐mediated amyloidosis

13. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis

14. Light Chain Testing Abnormalities Among Patients With Transthyretin Amyloid Cardiomyopathy Referred for Technetium-99m Pyrophosphate Imaging

16. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

17. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis

18. A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosis

20. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience

21. Tissue biopsy for the diagnosis of amyloidosis: experience from some centres

22. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable

23. HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (1234)

25. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

26. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy

27. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

29. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis

30. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis

31. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

34. Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy (240)

35. Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis: Global OLE Study (730)

36. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

37. Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

38. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

39. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

41. Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy

42. Long-Term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 2-Year Update (S27.008)

43. Responsiveness of Neuropathy Symptom and Change (NSC) Score Components in Inotersen Treatment of Hereditary Transthyretin Amyloidosis Polyneuropathy (P3.9-060)

44. Impact of Patisiran on Overall Health Status in hATTR Amyloidosis: Results from the APOLLO Trial (S27.007)

45. SAFETY OF INOTERSEN TREATMENT IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

46. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

48. Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis

50. Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial: Sensitivity Analyses Further Support the Primary Results

Catalog

Books, media, physical & digital resources